CS-1, a novel c-kithi+ acute myeloid leukemia cell line with dendritic cell differentiation capacity and absent immunogenicity

International Journal of Cancer

Volumn 105, Issue 2, 2003, Pages 232-240

  Erben, Ulrike ^a   Thiel, Eckhard ^a   Bittroff Leben, Alexandra ^a   Schoch, Claudia ^b   Fichtner, Iduna ^c   Dürkop, Horst ^a   Notter, Michael ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Acute myeloid leukemia M5a; Cell line; Dendritic cell differentiation; Immunosuppression; Poor immunogenicity

Indexed keywords

CD34 ANTIGEN; STEM CELL FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CELL CULTURE; CANCER RECURRENCE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOGENETICS; DENDRITIC CELL; HIGH RISK POPULATION; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; KARYOTYPE; LEUKEMIA CELL; LYMPHOCYTE ACTIVATION; MALE; MONOSOMY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

ANIMALS; ANTIGENS, CD34; BONE MARROW; CELL DIFFERENTIATION; CELL DIVISION; CHILD; CYTOKINES; DENDRITIC CELLS; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOPHENOTYPING; INJECTIONS, SUBCUTANEOUS; KARYOTYPING; LEUKEMIA, MONOCYTIC, ACUTE; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED NOD; MICE, SCID; PROTO-ONCOGENE PROTEINS C-KIT; SPLEEN; STEM CELL FACTOR; T-LYMPHOCYTES; TUMOR CELLS, CULTURED; TUMOR STEM CELLS;

EID: 0037431552     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11053     Document Type: Article

References (37)

1. Le Beau MM, Espinosa R 3rd, Davis EM, Eisenbart JD, Larson RA, Green ED. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood 1996;88:1930-35.
2. Druker BJ, Sawyers CL, Kantarijan H, Reese SF, Ford JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
3. Wells SJ, Bray RA, Stempora LL, Farhi DC. CD117/CD34 expression in leukemic blasts. Am J Clin Pathol 1996;106:192-5.
4. Buhring HJ, Ullrich A, Schaudt K, Muller CA, Busch FW. The product of the proto-oncogene c-kit (P145c-kit) is a human bone marrow surface antigen of hemopoietic precursor cells which is expressed on a subset of acute non-lymphoblastic leukemic cells. Leukemia 1991;5:854-60.
5. Kitayama H, Kanakura Y, Furitsu T, Tsujimura T, Oritani K, Ikeda H, Sugahara H, Mitsui H, Kanayama Y, Kitamura Y, Matsuzawa Y. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood 1995;85:790-8.
6. Broudy VC, Smith FO, Lin N, Zsebo KM, Egrie J, Bernstein ID. Blasts from patients with acute myelogenous leukemia express functional receptors for stem cell factor. Blood 1992;80:60-7.
7. Reuss-Borst MA, Buhring HJ, Schmidt H, Muller CA. AML: immunophenotypic heterogeneity and prognostic significance of c-kit expression. Leukemia 1994;8:258-63.
8. Blair A, Sutherland HJ. Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117) Exp Hematol 2000;28:660-71.
9. Narita M, Takahashi M, Liu A, Nikkuni K, Furukawa T, Toba K, Koyama S, Takai K, Sanada M, Aizawa Y. Leukemia blast-induced T-cell anergy demonstrated by leukemia-derived dendritic cells in acute myelogenous leukemia. Exp Hematol 2001;29:709-19.
10. Boyer MW, Waller EK, Bray RA, Unangst T, Johnson TS, Phillips C, Jurickova I, Winton EF, Yeager AM. Cytokine upregulation of the antigen presenting function of acute myeloid leukemia cells. Leukemia 2000;14:412-18.
11. Brouwer RE, Zwinderman KH, Kluin-Nelemans HC, van Luxemburg-Heijs SA, Willemze R, Falkenburg JH. Expression and induction of costimulatory and adhesion molecules on acute myeloid leukemic cells: implications for adoptive immunotherapy. Exp Hematol 2000;28:161-8.
12. Koeffler HP, Billing R, Lusis AJ, Sparkes R, Golde DW. An undifferentiated variant derived from the human acute myelogenous leukemia cell line (KG-1). Blood 1980;56:265-73.
13. Fonatsch C, Schaadt M, Kirchner H, Diehl V. A possible correlation between the degree of karyotype aberrations and the rate of sister chromatid exchanges in lymphoma lines. Int J Cancer 1980;26:749-56.
14. Mitelman F, ed. ISCN 1995: An international system for human cytogenetic nomenclature. Basel: S. Karger, 1995. VI+ 114p.
15. + blood progenitor cells. Stem Cells 1999;17:152-61.
16. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KA, Stein H, Mason DY. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984;32:219-29.
17. Mason DY, Stein H, Naiem M, Abdulaziz Z. Immunohistological analysis of human lymphoid tissue by double immunoenzymatic labelling. J Cancer Res Clin Oncol 1981;101:13-22.
18. Liang H, Fairman J, Claxton DF, Nowell PC, Green ED, Nagarajan L. Molecular anatomy of chromosome 7q deletions in myeloid neoplasms: evidence for multiple critical loci. Proc Natl Acad Sci USA 1998;95:3781-5.
19. Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Waller EK, Buck D. A novel 5-transmembrane hematopoietic stem cell antigen: Isolation, characterization, and molecular cloning. Blood 1997;90:5013-21.
20. Cole SR, Aylett GW, Harvey NL, Cambareri AC, Ashman LK. Increased expression of c-Kit or its ligand Steel Factor is not a common feature of adult acute myeloid leukaemia. Leukemia 1996;10:288-96.
21. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y, Matsuzawa Y, Kitamura Y, et. al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993;92:1736-44.
22. Beghini A, Peterlongo P, Ripamonti CB, Larizza L, Cairoli R, Morra E, Mecucci C. C-kit mutations in core binding factor leukemias. Blood 2000;95:726-7.
23. Gommerman JL, Sittaro D, Klebasz NZ, Williams DA, Berger SA. Differential stimulation of c-Kit mutants by membrane-bound and soluble Steel Factor correlates with leukemic potential. Blood 2000;96:3734-42.
24. Ning ZQ, Li J, Arceci RJ. Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. Oncogene 2001;20:4528-36.
25. Smolich BD, Yuen HA, West KA, Giles FJ, Albitar M, Cherrington JM. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood 2001;97:1413-21.
26. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-8.
27. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-7.
28. Hirano N, Takahashi T, Takahashi T, Ohtake S, Hirashima K, Emi N, Saito K, Hirano M, Shinohara K, Takeuchi M, Taketazu F, Tsunoda S, Ogura M, Omine M, Saito T, Yazaki Y, Ueda R, Hirai H. Expression of costimulatory molecules in human leukemias. Leukemia 1996;10:1168-76.
29. Buggins AG, Lea N, Gaken J, Darling D, Farzaneh F, Mufti GJ, Hirst WJ. Effect of costimulation and the microenvironment on antigen presentation by leukemic cells. Blood 1999;94:3479-90.
30. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992;71:1065-68.
31. Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 2001;182:207-14.
32. + T cells. J Exp Med 1996;184:1-8.
33. Harrison BD, Adams JA, Briggs M, Bereton ML, Yin JAL. Stimulation of autologous proliferative and cytotxic T-cell responses by "leukemic dendritic cells" derived from blast cells in acute myeloid leukemia. Blood 2001;97:2764-71.
34. Spisek R, Chevallier P, Morineau N, Milpied N, Avet-Loiseau H, Harousseau JL, Meflah K, Gregoire M. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin. Cancer Res 2002;62:2861-8.
35. - progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res 2000;60:4403-11.
36. Thurnher M, Zelle-Rieser C, Ramoner R, Bartsch G, Holtl L. The disabled dendritic cell. FASEB J 2001;15:1054-61.
37. Pulendran B, Smith JL, Caspary G, Brasel K, Pettit D, Maraskovsky E, Maliszewski CR. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci USA 1999;96:1036-41.